Description: ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Home Page: www.immunogen.com
IMGN Technical Analysis
830 Winter Street
Waltham,
MA
02451-1477
United States
Phone:
781 895 0600
Officers
| Name | Title |
|---|---|
| Mr. Mark Joseph Enyedy | Pres, CEO & Director |
| Ms. Susan Altschuller Ph.D. | Sr. VP & CFO |
| Dr. Anna Berkenblit M.D., MM.Sc | Sr. VP & Chief Medical Officer |
| Ms. Stacy A. Coen | Sr. VP & Chief Bus. Officer |
| Ms. Renee Lentini | VP of Fin. & Principal Accounting Officer |
| Ms. Courtney O'Konek | Sr. Director of Corp. Communications & Investor Relations |
| Mr. Daniel S. Char J.D. | Sr. VP & Chief Legal Officer |
| Ms. Audrey Bergan | Sr. VP & Chief HR Officer |
| Dr. Theresa G. Wingrove | Sr. VP of Regulatory Affairs & Quality |
| Dr. Mary Margaret Huizinga FACP, M.D., M.P.H. | Sr. VP & Head of Medical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.4114 |
| Price-to-Sales TTM: | 11.4754 |
| IPO Date: | 1989-11-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 106 |